Skip to main content
. Author manuscript; available in PMC: 2023 Sep 8.
Published in final edited form as: Sci Transl Med. 2023 Feb 8;15(682):eabn5649. doi: 10.1126/scitranslmed.abn5649

Fig. 2. D2C7+αCD40 therapy is antigen-dependent and demonstrates local and systemic antitumor immunity.

Fig. 2.

(A) Survival of CT-VIII+CT-2A tumor-bearing mice (n=10/group) treated with Ctrl, D2C7, αCD40, or D+C as indicated. (B) Survival of CT-VIII tumor-bearing mice (n=5/group) treated with Ctrl, D2C7, αCD40, or D+C as indicated in a model of metastatic cancer. (C-D) Representative H&E images of tumor sections from CT-VIII contralateral tumors (N=4–5/group), treated with control (C) or D+C (D) harvested 7-d post-therapy. Scale bar: 600 μm. (E) Percentage composition of tumor cells of entire tumor section cohort from C and D. Data are mean ± SEM. (F) Survival of parental CT-2A tumor-bearing mice (n=9–10/group) treated with Ctrl, D2C7, αCD40, or D+C as indicated. *P<0.05, **P<0.01.